9:41 AM
 | 
Jan 11, 2019
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Venture roundup: Apic, Stelexis, Biond, Keros

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) and cancer company Stelexis Therapeutics LLC (New York, N.Y.) each announced series A rounds of at least $40 million.

Other companies that announced venture rounds include Biond Biologics Ltd. (Misgav Industrial Park, Israel), which raised $17 million in a series B round, and Keros Therapeutics Inc. (Lexington, Mass.), which raised a $23 million series B round.

Apic plans to use its $40 million series A to develop APB-101, a "liver sparing" gene therapy treatment...

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >